Latebreakers: First-in-class CCR5 inhibitor OK'd

Article

Maraviroc (Selzentry, Pfizer), the first CCR5 inhibitor, was recently approved following priority review by the FDA.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.